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Background: Primary immunodeﬁciency disorders (PIDs) are an impor-
tant but under-diagnosed cause of childhood morbidity and mortality.
HSCT is the curative treatment for PIDs. Finding a matched donor is a
stumbling block. Moreover, presence of severe infections at the time of
transplants increases the transplant-related mortality (TRM. Poor infra-
structure in developing world adds to the Gordian knot. So, RIC HSCT has
been reported as a safer modality.
Objectives: To describe the feasibility and outcome of RIC HSCT for PIDs.
Methods: Twelve children with various PIDs, from August 2013 to August
2016 who underwent HSCT under our care were included. Clinical records
were analyzed retrospectively.
Results: Twelve children (SCID-2, DOCK-8 deﬁciency-1, Chediak-Higashi
Syndrome-1, WAS-3, HLH-2, GATA2 mutation-1 and CVID-1, HO-1 deﬁ-
ciency-1) with mean age 5.72 year underwent HSCT. Male: Female ratio
was 11:1. Mean follow-up 419 days (9 to 1209 days). Eight underwent
haploidentical HSCT three had matched sibling donor (MSD) HSCT, and
one had MUD HSCT. In seven T-cell replete haploidentical and one MUD
HSCT the conditioning was with serotherapy (Alemtuzumab-4 or Rabbit
Anti-Thymoglobulin-4) along with Fludarabine, Cyclophosphamide, Thio-
tepa and TBI in 5, Fludarabine and Treosulfan in 2 and Fludarabine and
Busulfan in 1. All received post transplant cyclophosphamide 50 mg/kg on
day 3 and 4 for GVHD prophylaxis along with tacrolimus and MMF. In one,
TCR alpha-beta/CD19 depleted haploidentical HSCT the conditioning was
Alemtuzumab, Fludarabine, Treosulfan and Thiotepa with no GVHD pro-
phylaxis. Two MSD were conditioned with Anti-Thymoglobulin, Fludar-
abine and Cyclophosphamide and GVHD prophylaxis was cyclosporine and
methotrexate and one MSD was given Alemtuzumaab, Fludarabine,
Cyclophosphamide and TBI with Tacrolimus and MMF for GVHD prophy-
laxis. Mean CD34+ cell dose was 14.24106/kg for 8 patients with PBSC
graft and 32.1106/kg for 4 patients who got bone marrow. Ten patients
engrafted and two died prior to engraftment with bacterial sepsis on day
+8 and day+14 respectively. Mean neutrophil engraftment was on 16.8 day.
One patient died with thrombotic microangiopathy on day+28. Eight
survivors are fully donor (>95%) and one had mixed chimerism (85%).
Acute GVHD grade I-II developed in 4 children. Chronic GVHD of skin
developed in two. CMV reactivation was seen in two and BCG reactivation
in two. Overall survival 75% and TRM 25%.
Conclusion: RIC HSCT constitutes a feasible option for PIDs in developing
world and gives a ray of hope for these patients.
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Abstract
Background/Objectives: Donor availability remains one of the major
challenges for performing hematopoetic stem cell transplantation (HSCT)
in the treatment of hematologic malignancies. Matched sibling or unre-
lated donor cannot be identiﬁed or mobilized in time for many patients.
HLA-haploidentical donor transplantation (HIDT) using Tcell replete grafts
and post-transplantation cyclophosphamide (PTCY) for control of allor-
eactivity has emerged as an important option for patients who lack a
donor. Post-transplant cyclophosphamide (PTCY) is not toxic to hemato-
poietic stem cells because of high expression of enzyme aldehyde dehy-
drogenase but it induces selective allodepletion by killing host and donor T
cells proliferating in response to donor and host cells, respectively. Thus,
PTCY decreases GvHD but doesnot effect GvL. We report here the feasi-
bility and outcome of HIDT in a developing world setting.
Designs/Methods: Six children with hematological malignancies and no
available matched donor underwent HIDT from Dec2013 to Sept2016. The
clinical records and investigation sheets were analyzed retrospectively.
Patient's follow-up ranged from Day+10 to Day+732 (Mean Day+278)
Results: Mean age was 4.88 year (1.6-9 years). M:F ¼ 3:3. All had hemato-
logical malignancies (High risk Acute myeloid leukemia-2, Relapsed acute
lymphoblastic leukemia-4) and all were in complete remission (CR) at thetime of transplant. Conditioning was Fludarabine (40mg/m2/day) from Day-
8 to day-5, Cyclophosphamide (14.5mg/kg/day) on Day-4 and Day-3, Thio-
tepa (8mg/kg/day) on Day-2 and TBI (2Gy) on Day-1. All patients received
haploidentical peripheral blood stem cells. Mean CD34+ cell dose was 12.7
106/kg/recipient weight. PTCY (50 mg/kg/day) was given on Day+3 and
Day+4. Tacrolimus and MMF were started from Day+5 for Graft-Vs-Host
disease (GvHD) prophylaxis. Supportive care along with Voriconazole and
Valacyclovir for antifungal and antiviral prophylaxis was given. Five patients
engrafted while one awaits engraftment (short follow-up). Mean neutrophil
engraftment was on 18.6 day. Immediate post-transplant period was un-
eventful. Only one patient had viral reactivation, who had Adenovirus
induced hemorrhagic cystitis on Day+44 which was successfully treated
with Cidofovir. Chimerism studies showed fully donor in all patients who
were post Day+100. One patient of Pre-B ALL relapsed on Day+406 of HIDT.
This patient was very difﬁcult to bring in remission even before the trans-
plant and is now being taken up for the next transplant. Acute GVHD was
not seen in any patient. Chronic GVHD of skin was seen in two patients
which was conservatively managed. All six patients are alive.
Conclusion: In hematological malignancies patients who have no
matched donor available, HIDT with PTCY constitutes a feasible and
effective option.
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Background: Haploidentical stem cell transplantation in children with
benign haematological disorders offers a unique opportunity to cure a
child who has no matched family donor. However, the associated chal-
lenges are different to conventional allograft making the options subop-
timal so far. Recent advances have made this procedure feasible in very
young children and we describe our experience in the use of this
technique.
Patients andmethods: The studywas conducted at the blood andmarrow
transplantation unit at Apollo Hospital, Chennai. Children aged up to 18
years who underwent haploidentical transplantation from 2002 to 2016
were included in the study.
Results: A total of 23 paediatric haploidentical stem cell transplantations
have been performed at our centre so far. Of these 16/23 (69.5%) have been
for benign disorders including Fanconi anaemia in 3, Haemophagocytic
LymphoHistiocytosis in 2, 1 with severe aplastic anaemia and 10 with
primary immunedeﬁciency disorders namely, severe combined immune-
deﬁciency in 6, 1 each with Wiskott Aldrich syndrome, Hyper IgM syn-
drome, MSMD and Adrenoleukodystrophy. The sources of stem cells were
from sibling and parent and bone marrow and peripheral blood in equal
numbers. Techniques of T depletion used were CD 34 selection in 1,
Campath in the bag in 1, TCR alpha/beta depletion 2, CD3/19 depletion in 1
and post transplant cyclophosphamide (PTCy) in 11 children.
In transplants where PTCy was used, conditioning included Fludarabine/
Treosulphan in primary immunedeﬁciency, Fludarabine/ Treosulphan/
single dose TBI 200cGy in HLH, Fludarabine/ Cyclophosphamide/ single
dose TBI 200cGy in Fanconi anaemia and severe aplastic anaemia. In the
child with ZAP70 mutation where TCR alpha/beta depletion was used,
conditioning regimen included Fludarabine/ Treosulphan/ Thiotepa/ ATG.
12/16 (75%) transplants resulted in engraftment by Day 16-21 post HSCT
with sustained complete chimerism. Hyper IgM syndrome and MSMD
were 2 conditions where primary rejection resulted in autologous recon-
stitution. Acute skin and gut GVHD of grade 2-3 was noted in 5/16 (31%)
which was responsive to steroids. Chronic skin and mouth GVHD has been
noted in 1 child. CMV reactivation was noted in 5/16 (31%) children
wherein 4 children achieved negative CMV copies on treatment with
Valganciclovir.
Mortality among this group of patients was found to be 6/16 (37.5%). In the
PTCy group, 3 children died of aspergillosis, severe ARDS and ruptured
peliosis hepatis respectively. Campath use resulted in refractory CMV
